logo

For the Inventor, By the Inventor

East Aurora, NY, United States of America

Carl W Porter

USPTO Granted Patents = 7

Average Co-Inventor Count = 1.7

ph-index = 4

Forward Citations = 56(Granted Patents)


Location History:

  • Falls Church, VA (US) (1981 - 1985)
  • East Aurora, NY (US) (1993 - 2003)

Company Filing History:

goldMedal5 out of 310 
 
Health Research, Inc.
 patents
silverMedal1 out of 10 
 
Pace University
 patents
bronzeMedal2 out of 832,966 
Other
 patents
where one patent can have more than one assignee

Years Active: 1981-2003

Loading Chart...
7 patents (USPTO):Explore Patents
1. 6531512 - Method of treating cancer in patients having a deficiency in p53 tumor suppressor gene (2003-03-11),
2. 6413775 - Polyamine analog-activated SSAT gene therapy (2002-07-02),
3. 5563125 - 5'-deoxy-5'-(substituted)alkylthioribose compounds and their (1996-10-08),
4. 5498522 - Methods for the use of spermidine/spermine N.sup.1 -acetyltransferase as (1996-03-12),
5. 5180714 - Adenosine compounds for the treatment of diseases caused by parasitic (1993-01-19),
6. 4494334 - Auxilliary fishing sinker (1985-01-22),
7. 4289457 - Combination sea valve and deballast pump (1981-09-15),

Title: Innovations in Cancer Treatment by Inventor Carl W. Porter

Introduction

Carl W. Porter, an innovative inventor based in East Aurora, NY, has made significant contributions to cancer treatment through his groundbreaking patents. With a total of seven patents to his name, he has focused on developing methods that enhance the efficacy of treatments for patients with specific genetic deficiencies.

Latest Patents

Among his notable recent inventions, Porter has developed a method of treating cancer in patients who have a deficiency in the p53 tumor suppressor gene. This method involves administering a therapeutically effective amount of polyamines, such as DENSPM, in combination with an anticancer agent. Additionally, he has introduced a polyamine analog-activated SSAT gene therapy, which aims to increase both the antitumor potency and selectivity of DENSPM. This method includes steps to increase SSAT mRNA levels and deliver an adequate dose of DENSPM to convert SSAT mRNA to enzyme activity, thereby promoting polyamine pool depletion and inhibiting tumor growth.

Career Highlights

Throughout his career, Carl W. Porter has been associated with several prestigious organizations, including Health Research, Inc. His work in these environments has significantly advanced the field of oncology, particularly in addressing the challenges faced by patients with compromised tumor suppression capabilities.

Collaborations

Porter has collaborated with notable professionals in the field, including Debora L. Kramer and Janice R. Sufrin. These partnerships have fostered a collaborative spirit in research and development, contributing to the successful implementation of his inventions.

Conclusion

Carl W. Porter is a distinguished inventor whose innovations continue to impact the treatment landscape for cancer patients. His commitment to addressing the needs of those with genetic vulnerabilities exemplifies the fusion of research and practical application in medical science. With a growing portfolio of patents, Porter remains a vital figure in the ongoing fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…